

Key: >>> ... marks correct (expected) result

> ... marks conditionally correct (acceptable) result

± ... marks the result not evaluated

N ... number of the results

Nrel ... relative number of the results

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set 1 and 2

(700) AB0 blood group

E1 and S1 (6) APR	>>>	3	Blood group: A	1,9 %
(14) Bio-Rad	>>>	50	Blood group: A	31 %
(40) Ortho Clinical Diagnostics	>>>	2	Blood group: A	1,2 %
(52) Dynex	>>>	2	Blood group: A	1,2 %
(64) Exbio Olomouc	>>>	7	Blood group: A	4,3 %
(80) DiaMed	>>>	14	Blood group: A	8,6 %
		1	Blood group: B	0,62 %
(159) Grifols	>>>	41	Blood group: A	25 %
(172) Immucor	>>>	21	Blood group: A	13 %
(173) Sanguin	>>>	8	Blood group: A	4,9 %
(174) IVT Imuno	>>>	7	Blood group: A	4,3 %
(203) ANTITOXIN	>>>	2	Blood group: A	1,2 %
(999) another manufacturer	>>>	4	Blood group: A	2,5 %
Total per sample: n = 162		Success: 99 %		
E2 and S2 (6) APR	>>>	3	Blood group: 0	1,9 %
(14) Bio-Rad	>>>	50	Blood group: 0	31 %
(40) Ortho Clinical Diagnostics	>>>	2	Blood group: 0	1,2 %
(52) Dynex	>>>	2	Blood group: 0	1,2 %
(64) Exbio Olomouc	>>>	7	Blood group: 0	4,3 %
(80) DiaMed	>>>	14	Blood group: 0	8,6 %
		1	Blood group: A	0,62 %
(159) Grifols	>>>	41	Blood group: 0	25 %
(172) Immucor	>>>	21	Blood group: 0	13 %
(173) Sanguin	>>>	8	Blood group: 0	4,9 %
(174) IVT Imuno	>>>	7	Blood group: 0	4,3 %
(203) ANTITOXIN	>>>	2	Blood group: 0	1,2 %
(999) another manufacturer	>>>	4	Blood group: 0	2,5 %
Total per sample: n = 162		Success: 99 %		
Total success: 99 %				

(703) A subgroup

E1 and S1 (0) not specified	>>>	51	A subgroup A1	100 %
Total per sample: n = 51		Success: 100 %		
E2 and S2 (0) not specified	>>>	51	Not specified	100 %
Total per sample: n = 51		Success: 100 %		
Total success: 100 %				

(705) Rh D antigen (blood-donor)

E1 and S1 (0) not specified	>>>	1	Positive (RhD+)	1,1 %
(6) APR	>>>	4	Positive (RhD+)	4,2 %
(14) Bio-Rad	>>>	29	Positive (RhD+)	31 %
(40) Ortho Clinical Diagnostics	>>>	1	Positive (RhD+)	1,1 %
(52) Dynex	>>>	1	Positive (RhD+)	1,1 %
(64) Exbio Olomouc	>>>	3	Positive (RhD+)	3,2 %
(80) DiaMed	>>>	4	Positive (RhD+)	4,2 %
(159) Grifols	>>>	19	Positive (RhD+)	20 %
(172) Immucor	>>>	22	Positive (RhD+)	23 %
(173) Sanguin	>>>	4	Positive (RhD+)	4,2 %
(174) IVT Imuno	>>>	3	Positive (RhD+)	3,2 %
(203) ANTITOXIN	>>>	2	Positive (RhD+)	2,1 %
(999) another manufacturer	>>>	2	Positive (RhD+)	2,1 %
Total per sample: n = 95		Success: 100 %		
E2 and S2 (0) not specified	>>>	1	Negative (RhD-)	1,1 %
(6) APR	>>>	4	Negative (RhD-)	4,2 %
(14) Bio-Rad	>>>	29	Negative (RhD-)	31 %
(40) Ortho Clinical Diagnostics	>>>	1	Negative (RhD-)	1,1 %
(52) Dynex	>>>	1	Negative (RhD-)	1,1 %
(64) Exbio Olomouc	>>>	3	Negative (RhD-)	3,2 %
(80) DiaMed	>>>	4	Negative (RhD-)	4,2 %
(159) Grifols	>>>	19	Negative (RhD-)	20 %
(172) Immucor	>>>	22	Negative (RhD-)	23 %
(173) Sanguin	>>>	4	Negative (RhD-)	4,2 %
(174) IVT Imuno	>>>	3	Negative (RhD-)	3,2 %
(203) ANTITOXIN	>>>	2	Negative (RhD-)	2,1 %

EQA round: IH4/22 - Blood Group Serology

Test	Sample	Group	N	Result	N _{rel}	
E2 and S2 (999) another manufacturer			>>>	2 Negative (RhD-)	2,1 %	
	Total per sample: n = 95		Success: 100 %			
Total success: 100 %						
(709) Rh D antigen (recipient)						
E1 and S1 (6) APR			>>>	3 Positive (RhD+)	2,0 %	
	(14)	Bio-Rad	>>>	46 Positive (RhD+)	30 %	
	(40)	Ortho Clinical Diagnostics	>>>	2 Positive (RhD+)	1,3 %	
	(50)	Merck	>>>	1 Positive (RhD+)	0,66 %	
	(52)	Dynex	>>>	2 Positive (RhD+)	1,3 %	
	(64)	Exbio Olomouc	>>>	6 Positive (RhD+)	3,9 %	
	(80)	DiaMed	>>>	1 Negative (RhD-)	0,66 %	
	(159)	Grifols	>>>	11 Positive (RhD+)	7,2 %	
	(172)	Immucor	>>>	40 Positive (RhD+)	26 %	
	(173)	Sanguin	>>>	22 Positive (RhD+)	14 %	
	(173)	Sanguin	>>>	5 Positive (RhD+)	3,3 %	
	(174)	IVT Imuno	>>>	6 Positive (RhD+)	3,9 %	
	(203)	ANTITOXIN	>>>	2 Positive (RhD+)	1,3 %	
	(999)	another manufacturer	>>>	5 Positive (RhD+)	3,3 %	
	Total per sample: n = 152		Success: 99 %			
	E2 and S2 (6) APR			>>>	3 Negative (RhD-)	2,0 %
		(14)	Bio-Rad	>>>	46 Negative (RhD-)	30 %
(40)		Ortho Clinical Diagnostics	>>>	2 Negative (RhD-)	1,3 %	
(50)		Merck	>>>	1 Negative (RhD-)	0,66 %	
(52)		Dynex	>>>	2 Negative (RhD-)	1,3 %	
(64)		Exbio Olomouc	>>>	6 Negative (RhD-)	3,9 %	
(80)		DiaMed	>>>	12 Negative (RhD-)	7,9 %	
(159)		Grifols	>>>	40 Negative (RhD-)	26 %	
(172)		Immucor	>>>	22 Negative (RhD-)	14 %	
(173)		Sanguin	>>>	5 Negative (RhD-)	3,3 %	
(174)		IVT Imuno	>>>	6 Negative (RhD-)	3,9 %	
(203)		ANTITOXIN	>>>	2 Negative (RhD-)	1,3 %	
(999)		another manufacturer	>>>	5 Negative (RhD-)	3,3 %	
Total per sample: n = 152		Success: 100 %				
Total success: 99 %						
(715) Antigen C						
E1 and S1 (6) APR				>>>	1 Positive	1,2 %
	(14)	Bio-Rad	>>>	33 Positive	40 %	
	(50)	Merck	>>>	1 Positive	1,2 %	
	(64)	Exbio Olomouc	>>>	1 Positive	1,2 %	
	(80)	DiaMed	>>>	6 Positive	7,3 %	
	(159)	Grifols	>>>	18 Positive	22 %	
	(172)	Immucor	>>>	14 Positive	17 %	
	(173)	Sanguin	>>>	2 Positive	2,4 %	
	(174)	IVT Imuno	>>>	2 Positive	2,4 %	
	(203)	ANTITOXIN	>>>	3 Positive	3,7 %	
	(999)	another manufacturer	>>>	1 Positive	1,2 %	
Total per sample: n = 82		Success: 100 %				
E2 and S2 (6) APR			>>>	1 Negative	1,2 %	
	(14)	Bio-Rad	>>>	33 Negative	40 %	
	(50)	Merck	>>>	1 Negative	1,2 %	
	(64)	Exbio Olomouc	>>>	1 Negative	1,2 %	
	(80)	DiaMed	>>>	6 Negative	7,3 %	
	(159)	Grifols	>>>	18 Negative	22 %	
	(172)	Immucor	>>>	14 Negative	17 %	
	(173)	Sanguin	>>>	2 Negative	2,4 %	
	(174)	IVT Imuno	>>>	2 Negative	2,4 %	
	(203)	ANTITOXIN	>>>	3 Negative	3,7 %	
	(999)	another manufacturer	>>>	1 Negative	1,2 %	
Total per sample: n = 82		Success: 100 %				
Total success: 100 %						
(716) Antigen c						
E1 and S1 (6) APR			>>>	1 Negative	1,2 %	
	(14)	Bio-Rad	>>>	33 Negative	40 %	
	(50)	Merck	>>>	1 Negative	1,2 %	
	(64)	Exbio Olomouc	>>>	1 Negative	1,2 %	
	(80)	DiaMed	>>>	6 Negative	7,3 %	
	(159)	Grifols	>>>	18 Negative	22 %	

EQA round: IH4/22 - Blood Group Serology

Deadline: 18.11.2022

Test	Sample	Group	N	Result	N _{rel}
E1 and S1	(172)	Immucor	>>>	14 Negative	17 %
	(173)	Sanguin	>>>	2 Negative	2,4 %
	(174)	IVT Imuno	>>>	2 Negative	2,4 %
	(203)	ANTITOXIN	>>>	3 Negative	3,7 %
	(999)	another manufacturer	>>>	1 Negative	1,2 %
	Total per sample: n = 82			Success: 100 %	
E2 and S2	(6)	APR	>>>	1 Positive	1,2 %
	(14)	Bio-Rad	>>>	33 Positive	40 %
	(50)	Merck	>>>	1 Positive	1,2 %
	(64)	Exbio Olomouc	>>>	1 Positive	1,2 %
	(80)	DiaMed	>>>	6 Positive	7,3 %
	(159)	Grifols	>>>	18 Positive	22 %
	(172)	Immucor	>>>	14 Positive	17 %
	(173)	Sanguin	>>>	2 Positive	2,4 %
	(174)	IVT Imuno	>>>	2 Positive	2,4 %
	(203)	ANTITOXIN	>>>	3 Positive	3,7 %
	(999)	another manufacturer	>>>	1 Positive	1,2 %
Total per sample: n = 82			Success: 100 %		
Total success: 100 %					

(717) Antigen Cw

E1 and S1	(6)	APR	>>>	1 Negative	1,5 %
	(14)	Bio-Rad	>>>	22 Negative	34 %
	(50)	Merck	>>>	1 Negative	1,5 %
	(64)	Exbio Olomouc	>>>	1 Negative	1,5 %
	(80)	DiaMed	>>>	1 Negative	1,5 %
	(159)	Grifols	>>>	18 Negative	28 %
	(172)	Immucor	>>>	13 Negative	20 %
	(173)	Sanguin	>>>	2 Negative	3,1 %
	(174)	IVT Imuno	>>>	4 Negative	6,2 %
	(203)	ANTITOXIN	>>>	2 Negative	3,1 %
Total per sample: n = 65			Success: 100 %		
E2 and S2	(6)	APR	>>>	1 Negative	1,5 %
	(14)	Bio-Rad	>>>	22 Negative	34 %
	(50)	Merck	>>>	1 Negative	1,5 %
	(64)	Exbio Olomouc	>>>	1 Negative	1,5 %
	(80)	DiaMed	>>>	1 Negative	1,5 %
	(159)	Grifols	>>>	18 Negative	28 %
	(172)	Immucor	>>>	13 Negative	20 %
	(173)	Sanguin	>>>	2 Negative	3,1 %
	(174)	IVT Imuno	>>>	4 Negative	6,2 %
	(203)	ANTITOXIN	>>>	2 Negative	3,1 %
Total per sample: n = 65			Success: 100 %		
Total success: 100 %					

(718) Antigen E

E1 and S1	(6)	APR	>>>	1 Negative	1,2 %
	(14)	Bio-Rad	>>>	33 Negative	40 %
	(50)	Merck	>>>	1 Negative	1,2 %
	(64)	Exbio Olomouc	>>>	1 Negative	1,2 %
	(80)	DiaMed	>>>	6 Negative	7,3 %
	(159)	Grifols	>>>	18 Negative	22 %
	(172)	Immucor	>>>	14 Negative	17 %
	(173)	Sanguin	>>>	2 Negative	2,4 %
	(174)	IVT Imuno	>>>	2 Negative	2,4 %
	(203)	ANTITOXIN	>>>	3 Negative	3,7 %
	(999)	another manufacturer	>>>	1 Negative	1,2 %
Total per sample: n = 82			Success: 100 %		
E2 and S2	(6)	APR	>>>	1 Negative	1,2 %
	(14)	Bio-Rad	>>>	33 Negative	40 %
	(50)	Merck	>>>	1 Negative	1,2 %
	(64)	Exbio Olomouc	>>>	1 Negative	1,2 %
	(80)	DiaMed	>>>	6 Negative	7,3 %
	(159)	Grifols	>>>	18 Negative	22 %
	(172)	Immucor	>>>	14 Negative	17 %
	(173)	Sanguin	>>>	2 Negative	2,4 %
	(174)	IVT Imuno	>>>	2 Negative	2,4 %
	(203)	ANTITOXIN	>>>	3 Negative	3,7 %
(999)	another manufacturer	>>>	1 Negative	1,2 %	
Total per sample: n = 82			Success: 100 %		

Test		N	Result	N _{rel}
Sample	Group			
Total success: 100 %				
(719) Antigen e				
E1 and S1	(6) APR	>>> 1	Positive	1,2 %
	(14) Bio-Rad	>>> 32	Positive	39 %
	(17) Biogema	>>> 1	Positive	1,2 %
	(50) Merck	>>> 1	Positive	1,2 %
	(64) Exbio Olomouc	>>> 1	Positive	1,2 %
	(80) DiaMed	>>> 6	Positive	7,3 %
	(159) Grifols	>>> 18	Positive	22 %
	(172) Immucor	>>> 14	Positive	17 %
	(173) Sanguin	>>> 2	Positive	2,4 %
	(174) IVT Imuno	>>> 2	Positive	2,4 %
	(203) ANTITOXIN	>>> 3	Positive	3,7 %
	(999) another manufacturer	>>> 1	Positive	1,2 %
Total per sample: n = 82		Success: 100 %		
E2 and S2	(6) APR	>>> 1	Positive	1,2 %
	(14) Bio-Rad	>>> 32	Positive	39 %
	(17) Biogema	>>> 1	Positive	1,2 %
	(50) Merck	>>> 1	Positive	1,2 %
	(64) Exbio Olomouc	>>> 1	Positive	1,2 %
	(80) DiaMed	>>> 6	Positive	7,3 %
	(159) Grifols	>>> 18	Positive	22 %
	(172) Immucor	>>> 14	Positive	17 %
	(173) Sanguin	>>> 2	Positive	2,4 %
	(174) IVT Imuno	>>> 2	Positive	2,4 %
	(203) ANTITOXIN	>>> 3	Positive	3,7 %
	(999) another manufacturer	>>> 1	Positive	1,2 %
Total per sample: n = 82		Success: 100 %		
Total success: 100 %				
(720) Antigen K				
E1 and S1	(6) APR	>>> 1	Negative	1,2 %
	(14) Bio-Rad	>>> 30	Negative	35 %
	(50) Merck	>>> 1	Negative	1,2 %
	(80) DiaMed	>>> 6	Negative	7,1 %
	(159) Grifols	>>> 22	Negative	26 %
	(172) Immucor	>>> 14	Negative	16 %
	(173) Sanguin	>>> 3	Negative	3,5 %
	(174) IVT Imuno	>>> 4	Negative	4,7 %
	(203) ANTITOXIN	>>> 2	Negative	2,4 %
	(999) another manufacturer	>>> 2	Negative	2,4 %
Total per sample: n = 85		Success: 100 %		
E2 and S2	(6) APR	>>> 1	Negative	1,2 %
	(14) Bio-Rad	>>> 30	Negative	35 %
	(50) Merck	>>> 1	Negative	1,2 %
	(80) DiaMed	>>> 6	Negative	7,1 %
	(159) Grifols	>>> 22	Negative	26 %
	(172) Immucor	>>> 14	Negative	16 %
	(173) Sanguin	>>> 3	Negative	3,5 %
	(174) IVT Imuno	>>> 4	Negative	4,7 %
	(203) ANTITOXIN	>>> 2	Negative	2,4 %
	(999) another manufacturer	>>> 2	Negative	2,4 %
Total per sample: n = 85		Success: 100 %		
Total success: 100 %				
(721) Antigen k				
E1 and S1	(14) Bio-Rad	>>> 13	Positive	30 %
	(64) Exbio Olomouc	>>> 5	Positive	12 %
	(80) DiaMed	>>> 2	Positive	4,7 %
	(159) Grifols	>>> 4	Positive	9,3 %
	(172) Immucor	>>> 5	Positive	12 %
	(173) Sanguin	>>> 7	Positive	16 %
	(174) IVT Imuno	>>> 2	Positive	4,7 %
	(203) ANTITOXIN	>>> 4	Positive	9,3 %
	(999) another manufacturer	>>> 1	Positive	2,3 %
Total per sample: n = 43		Success: 100 %		
E2 and S2	(14) Bio-Rad	>>> 13	Positive	30 %
	(64) Exbio Olomouc	>>> 5	Positive	12 %
	(80) DiaMed	>>> 2	Positive	4,7 %
	(159) Grifols	>>> 4	Positive	9,3 %

EQA round: IH4/22 - Blood Group Serology

Deadline: 18.11.2022

Test

Sample	Group	N	Result	N _{rel}
E2 and S2 (172)	Immucor	>>>	5 Positive	12 %
(173)	Sanguin	>>>	7 Positive	16 %
(174)	IVT Imuno	>>>	2 Positive	4,7 %
(203)	ANTITOXIN	>>>	4 Positive	9,3 %
(999)	another manufacturer	>>>	1 Positive	2,3 %
Total per sample: n = 43		Success: 100 %		
Total success: 100 %				

(722) Antigen M

E1 and S1 (6)	APR	>>>	1 Positive	2,5 %
(14)	Bio-Rad	>>>	9 Positive	23 %
(52)	Dynex	>>>	2 Positive	5,0 %
(64)	Exbio Olomouc	>>>	2 Positive	5,0 %
(80)	DiaMed	>>>	1 Positive	2,5 %
(159)	Grifols	>>>	4 Positive	10 %
(172)	Immucor	>>>	15 Positive	38 %
(173)	Sanguin	>>>	2 Positive	5,0 %
(183)	Immunodiagnostic Systems	>>>	1 Positive	2,5 %
(203)	ANTITOXIN	>>>	3 Positive	7,5 %
Total per sample: n = 40		Success: 100 %		

E2 and S2 (6)	APR	>>>	1 Positive	2,5 %
(14)	Bio-Rad	>>>	9 Positive	23 %
(52)	Dynex	>>>	2 Positive	5,0 %
(64)	Exbio Olomouc	>>>	2 Positive	5,0 %
(80)	DiaMed	>>>	1 Positive	2,5 %
(159)	Grifols	>>>	4 Positive	10 %
(172)	Immucor	>>>	15 Positive	38 %
(173)	Sanguin	>>>	2 Positive	5,0 %
(183)	Immunodiagnostic Systems	>>>	1 Positive	2,5 %
(203)	ANTITOXIN	>>>	3 Positive	7,5 %
Total per sample: n = 40		Success: 100 %		

Total success: 100 %

(723) Antigen N

E1 and S1 (6)	APR	>>>	1 Positive	2,7 %
(14)	Bio-Rad	>>>	10 Positive	27 %
(52)	Dynex	>>>	2 Positive	5,4 %
(64)	Exbio Olomouc	>>>	1 Positive	2,7 %
(80)	DiaMed	>>>	1 Positive	2,7 %
(159)	Grifols	>>>	4 Positive	11 %
(172)	Immucor	>>>	12 Positive	32 %
(173)	Sanguin	>>>	2 Positive	5,4 %
(183)	Immunodiagnostic Systems	>>>	1 Positive	2,7 %
(203)	ANTITOXIN	>>>	3 Positive	8,1 %
Total per sample: n = 37		Success: 100 %		

E2 and S2 (6)	APR	>>>	1 Negative	2,7 %
(14)	Bio-Rad	>>>	10 Negative	27 %
(52)	Dynex	>>>	2 Negative	5,4 %
(64)	Exbio Olomouc	>>>	1 Negative	2,7 %
(80)	DiaMed	>>>	1 Negative	2,7 %
(159)	Grifols	>>>	4 Negative	11 %
(172)	Immucor	>>>	12 Negative	32 %
(173)	Sanguin	>>>	2 Negative	5,4 %
(183)	Immunodiagnostic Systems	>>>	1 Negative	2,7 %
(203)	ANTITOXIN	>>>	3 Negative	8,1 %
Total per sample: n = 37		Success: 100 %		

Total success: 100 %

(724) Antigen S

E1 and S1 (6)	APR	>>>	1 Positive	2,5 %
(14)	Bio-Rad	>>>	11 Positive	28 %
(50)	Merck	>>>	1 Positive	2,5 %
(52)	Dynex	>>>	2 Positive	5,0 %
(64)	Exbio Olomouc	>>>	2 Positive	5,0 %
(80)	DiaMed	>>>	1 Positive	2,5 %
(159)	Grifols	>>>	5 Positive	13 %
(172)	Immucor	>>>	8 Positive	20 %
(173)	Sanguin	>>>	4 Positive	10 %
(174)	IVT Imuno	>>>	2 Positive	5,0 %
(203)	ANTITOXIN	>>>	3 Positive	7,5 %

EQA round: IH4/22 - Blood Group Serology

Deadline: 18.11.2022

Test

Sample	Group	N	Result	N _{rel}
Total per sample: n = 40		Success: 100 %		
E2 and S2	(6) APR	>>> 1	Positive	2,5 %
	(14) Bio-Rad	>>> 11	Positive	28 %
	(50) Merck	>>> 1	Positive	2,5 %
	(52) Dynex	>>> 2	Positive	5,0 %
	(64) Exbio Olomouc	>>> 2	Positive	5,0 %
	(80) DiaMed	>>> 1	Positive	2,5 %
	(159) Grifols	>>> 5	Positive	13 %
	(172) Immucor	>>> 8	Positive	20 %
	(173) Sanguin	>>> 4	Positive	10 %
	(174) IVT Imuno	>>> 2	Positive	5,0 %
	(203) ANTITOXIN	>>> 3	Positive	7,5 %
Total per sample: n = 40		Success: 100 %		

Total success: 100 %

(725) Antigen s

E1 and S1	(6) APR	>>> 1	Positive	2,5 %
	(14) Bio-Rad	>>> 11	Positive	28 %
	(52) Dynex	>>> 1	Positive	2,5 %
	(64) Exbio Olomouc	>>> 3	Positive	7,5 %
	(80) DiaMed	>>> 1	Positive	2,5 %
	(159) Grifols	>>> 5	Positive	13 %
	(172) Immucor	>>> 8	Positive	20 %
	(173) Sanguin	>>> 5	Positive	13 %
	(174) IVT Imuno	>>> 2	Positive	5,0 %
	(203) ANTITOXIN	>>> 3	Positive	7,5 %
Total per sample: n = 40		Success: 100 %		
E2 and S2	(6) APR	>>> 1	Positive	2,5 %
	(14) Bio-Rad	>>> 11	Positive	28 %
	(52) Dynex	>>> 1	Positive	2,5 %
	(64) Exbio Olomouc	>>> 3	Positive	7,5 %
	(80) DiaMed	>>> 1	Positive	2,5 %
	(159) Grifols	>>> 5	Positive	13 %
	(172) Immucor	>>> 8	Positive	20 %
	(173) Sanguin	>>> 5	Positive	13 %
	(174) IVT Imuno	>>> 2	Positive	5,0 %
	(203) ANTITOXIN	>>> 3	Positive	7,5 %
Total per sample: n = 40		Success: 100 %		

Total success: 100 %

(726) Antigen P1

E1 and S1	(6) APR	>>> 1	Positive	3,4 %
	(14) Bio-Rad	>>> 7	Positive	24 %
	(64) Exbio Olomouc	>>> 3	Positive	10 %
	(80) DiaMed	>>> 1	Positive	3,4 %
	(159) Grifols	>>> 1	Positive	3,4 %
	(172) Immucor	>>> 1	Negative	3,4 %
		>>> 8	Positive	28 %
	(173) Sanguin	>>> 5	Positive	17 %
	(174) IVT Imuno	>>> 1	Positive	3,4 %
	(203) ANTITOXIN	>>> 1	Positive	3,4 %
Total per sample: n = 29		Success: 97 %		
E2 and S2	(6) APR	>>> 1	Positive	3,4 %
	(14) Bio-Rad	>>> 7	Positive	24 %
	(64) Exbio Olomouc	>>> 3	Positive	10 %
	(80) DiaMed	>>> 1	Positive	3,4 %
	(159) Grifols	>>> 1	Positive	3,4 %
	(172) Immucor	>>> 9	Positive	31 %
	(173) Sanguin	>>> 5	Positive	17 %
	(174) IVT Imuno	>>> 1	Positive	3,4 %
	(203) ANTITOXIN	>>> 1	Positive	3,4 %
Total per sample: n = 29		Success: 100 %		

Total success: 97 %

(727) Antigen Fya

E1 and S1	(14) Bio-Rad	>>> 14	Negative	34 %
	(64) Exbio Olomouc	>>> 3	Negative	7,3 %
	(80) DiaMed	>>> 1	Negative	2,4 %
	(159) Grifols	>>> 5	Negative	12 %
	(172) Immucor	>>> 10	Negative	24 %
	(173) Sanguin	>>> 5	Negative	12 %

EQA round: IH4/22 - Blood Group Serology

Deadline: 18.11.2022

Test	Sample	Group	N	Result	N _{rel}
E1 and S1 (174) IVT Imuno		>>>	1	Negative	2,4 %
	(203) ANTITOXIN	>>>	2	Negative	4,9 %
Total per sample: n = 41		Success: 100 %			
E2 and S2 (14) Bio-Rad		>>>	14	Negative	34 %
	(64) Exbio Olomouc	>>>	3	Negative	7,3 %
	(80) DiaMed	>>>	1	Negative	2,4 %
	(159) Grifols	>>>	5	Negative	12 %
	(172) Immucor	>>>	10	Negative	24 %
	(173) Sanguin	>>>	5	Negative	12 %
	(174) IVT Imuno	>>>	1	Negative	2,4 %
	(203) ANTITOXIN	>>>	2	Negative	4,9 %
Total per sample: n = 41		Success: 100 %			
Total success: 100 %					

(728) Antigen Fyb

E1 and S1 (14) Bio-Rad		>>>	14	Positive	34 %
	(64) Exbio Olomouc	>>>	3	Positive	7,3 %
	(80) DiaMed	>>>	1	Positive	2,4 %
	(159) Grifols	>>>	5	Positive	12 %
	(172) Immucor	>>>	9	Positive	22 %
	(173) Sanguin	>>>	5	Positive	12 %
	(174) IVT Imuno	>>>	1	Positive	2,4 %
	(203) ANTITOXIN	>>>	3	Positive	7,3 %
Total per sample: n = 41		Success: 100 %			
E2 and S2 (14) Bio-Rad		>>>	14	Positive	34 %
	(64) Exbio Olomouc	>>>	3	Positive	7,3 %
	(80) DiaMed	>>>	1	Positive	2,4 %
	(159) Grifols	>>>	5	Positive	12 %
	(172) Immucor	>>>	9	Positive	22 %
	(173) Sanguin	>>>	5	Positive	12 %
	(174) IVT Imuno	>>>	1	Positive	2,4 %
	(203) ANTITOXIN	>>>	3	Positive	7,3 %
Total per sample: n = 41		Success: 100 %			
Total success: 100 %					

(729) Antigen Jka

E1 and S1 (6) APR		>>>	1	Negative	2,4 %
	(14) Bio-Rad	>>>	12	Negative	29 %
	(50) Merck	>>>	1	Negative	2,4 %
	(52) Dynex	>>>	2	Negative	4,9 %
	(64) Exbio Olomouc	>>>	1	Negative	2,4 %
	(80) DiaMed	>>>	1	Negative	2,4 %
	(159) Grifols	>>>	6	Negative	15 %
	(172) Immucor	>>>	9	Negative	22 %
	(173) Sanguin	>>>	5	Negative	12 %
	(203) ANTITOXIN	>>>	3	Negative	7,3 %
Total per sample: n = 41		Success: 100 %			
E2 and S2 (6) APR		>>>	1	Positive	2,4 %
	(14) Bio-Rad	>>>	12	Positive	29 %
	(50) Merck	>>>	1	Positive	2,4 %
	(52) Dynex	>>>	2	Positive	4,9 %
	(64) Exbio Olomouc	>>>	1	Positive	2,4 %
	(80) DiaMed	>>>	1	Positive	2,4 %
	(159) Grifols	>>>	6	Positive	15 %
	(172) Immucor	>>>	9	Positive	22 %
	(173) Sanguin	>>>	5	Positive	12 %
	(203) ANTITOXIN	>>>	3	Positive	7,3 %
Total per sample: n = 41		Success: 100 %			
Total success: 100 %					

(730) Antigen Jkb

E1 and S1 (6) APR		>>>	1	Positive	2,4 %
	(14) Bio-Rad	>>>	11	Positive	27 %
	(50) Merck	>>>	1	Positive	2,4 %
	(52) Dynex	>>>	2	Positive	4,9 %
	(64) Exbio Olomouc	>>>	1	Positive	2,4 %
	(80) DiaMed	>>>	1	Positive	2,4 %
	(159) Grifols	>>>	6	Positive	15 %
	(172) Immucor	>>>	9	Positive	22 %
	(173) Sanguin	>>>	6	Positive	15 %

EQA round: IH4/22 - Blood Group Serology

Test	Sample	Group	N	Result	N _{rel}	
E1 and S1 (203) ANTITOXIN		>>>	3	Positive	7,3 %	
	Total per sample: n = 41		Success: 100 %			
E2 and S2 (6) APR		>>>	1	Positive	2,4 %	
	(14) Bio-Rad	>>>	11	Positive	27 %	
	(50) Merck	>>>	1	Positive	2,4 %	
	(52) Dynex	>>>	2	Positive	4,9 %	
	(64) Exbio Olomouc	>>>	1	Positive	2,4 %	
	(80) DiaMed	>>>	1	Positive	2,4 %	
	(159) Grifols	>>>	6	Positive	15 %	
	(172) Immucor	>>>	9	Positive	22 %	
	(173) Sanguin	>>>	6	Positive	15 %	
	(203) ANTITOXIN	>>>	3	Positive	7,3 %	
Total per sample: n = 41		Success: 100 %				
Total success: 100 %						
(731) Antigen Lua						
E1 and S1 (14) Bio-Rad		>>>	11	Negative	44 %	
	(64) Exbio Olomouc	>>>	2	Negative	8,0 %	
	(80) DiaMed	>>>	2	Negative	8,0 %	
	(159) Grifols	>>>	4	Negative	16 %	
	(172) Immucor	>>>	4	Negative	16 %	
	(173) Sanguin	>>>	1	Negative	4,0 %	
	(203) ANTITOXIN	>>>	1	Negative	4,0 %	
	Total per sample: n = 25		Success: 100 %			
E2 and S2 (14) Bio-Rad		>>>	11	Negative	44 %	
	(64) Exbio Olomouc	>>>	2	Negative	8,0 %	
	(80) DiaMed	>>>	2	Negative	8,0 %	
	(159) Grifols	>>>	4	Negative	16 %	
	(172) Immucor	>>>	4	Negative	16 %	
	(173) Sanguin	>>>	1	Negative	4,0 %	
	(203) ANTITOXIN	>>>	1	Negative	4,0 %	
	Total per sample: n = 25		Success: 100 %			
Total success: 100 %						
(732) Antigen Lub						
E1 and S1 (14) Bio-Rad		>>>	9	Positive	36 %	
	(64) Exbio Olomouc	>>>	3	Positive	12 %	
	(80) DiaMed	>>>	2	Positive	8,0 %	
	(159) Grifols	>>>	3	Positive	12 %	
	(172) Immucor	>>>	4	Positive	16 %	
	(173) Sanguin	>>>	1	Positive	4,0 %	
	(203) ANTITOXIN	>>>	2	Positive	8,0 %	
	(999) another manufacturer	>>>	1	Positive	4,0 %	
	Total per sample: n = 25		Success: 100 %			
E2 and S2 (14) Bio-Rad		>>>	9	Positive	36 %	
	(64) Exbio Olomouc	>>>	3	Positive	12 %	
	(80) DiaMed	>>>	2	Positive	8,0 %	
	(159) Grifols	>>>	3	Positive	12 %	
	(172) Immucor	>>>	4	Positive	16 %	
	(173) Sanguin	>>>	1	Positive	4,0 %	
	(203) ANTITOXIN	>>>	2	Positive	8,0 %	
	(999) another manufacturer	>>>	1	Positive	4,0 %	
	Total per sample: n = 25		Success: 100 %			
Total success: 100 %						
(733) Antigen Lea						
E1 and S1 (0) not specified		>>>	1	Negative	2,9 %	
	(14) Bio-Rad	>>>	10	Negative	29 %	
	(50) Merck	>>>	1	Negative	2,9 %	
	(52) Dynex	>>>	2	Negative	5,9 %	
	(64) Exbio Olomouc	>>>	1	Negative	2,9 %	
	(80) DiaMed	>>>	1	Negative	2,9 %	
	(159) Grifols	>>>	2	Negative	5,9 %	
				1	Positive	2,9 %
	(172) Immucor	>>>	9	Negative	26 %	
	(173) Sanguin	>>>	2	Negative	5,9 %	
	(174) IVT Imuno	>>>	2	Negative	5,9 %	
	(203) ANTITOXIN	>>>	2	Negative	5,9 %	
	Total per sample: n = 34		Success: 97 %			
E2 and S2 (0) not specified		>>>	1	Negative	2,9 %	

Test		N	Result	N _{rel}
Sample	Group			
E2 and S2	(14) Bio-Rad	>>> 10	Negative	29 %
	(50) Merck	>>> 1	Negative	2,9 %
	(52) Dynex	>>> 2	Negative	5,9 %
	(64) Exbio Olomouc	>>> 1	Negative	2,9 %
	(80) DiaMed	>>> 1	Negative	2,9 %
	(159) Grifols	>>> 3	Negative	8,8 %
	(172) Immucor	>>> 9	Negative	26 %
	(173) Sanguin	>>> 2	Negative	5,9 %
	(174) IVT Imuno	>>> 2	Negative	5,9 %
	(203) ANTITOXIN	>>> 2	Negative	5,9 %
Total per sample: n = 34		Success: 100 %		
Total success: 97 %				

(734) Antigen Leb

E1 and S1	(0) not specified	>>> 1	Negative	2,9 %
	(14) Bio-Rad	>>> 10	Negative	29 %
	(50) Merck	>>> 1	Negative	2,9 %
	(52) Dynex	>>> 2	Negative	5,9 %
	(64) Exbio Olomouc	>>> 1	Negative	2,9 %
	(80) DiaMed	>>> 1	Negative	2,9 %
	(159) Grifols	>>> 3	Negative	8,8 %
	(172) Immucor	>>> 9	Negative	26 %
	(173) Sanguin	>>> 2	Negative	5,9 %
	(174) IVT Imuno	>>> 2	Negative	5,9 %
	(203) ANTITOXIN	>>> 2	Negative	5,9 %
Total per sample: n = 34		Success: 100 %		
E2 and S2	(0) not specified	>>> 1	Positive	2,9 %
	(14) Bio-Rad	>>> 10	Positive	29 %
	(50) Merck	>>> 1	Positive	2,9 %
	(52) Dynex	>>> 2	Positive	5,9 %
	(64) Exbio Olomouc	>>> 1	Positive	2,9 %
	(80) DiaMed	>>> 1	Positive	2,9 %
	(159) Grifols	>>> 3	Positive	8,8 %
	(172) Immucor	>>> 9	Positive	26 %
	(173) Sanguin	>>> 2	Positive	5,9 %
	(174) IVT Imuno	>>> 2	Positive	5,9 %
	(203) ANTITOXIN	>>> 2	Positive	5,9 %
Total per sample: n = 34		Success: 100 %		
Total success: 100 %				

(737) Direct Coombs (antiglobulin) test

E1 and S1	(6) APR	>>> 1	Negative	0,74 %
	(14) Bio-Rad	>>> 61	Negative	45 %
	(40) Ortho Clinical Diagnostics	>>> 2	Negative	1,5 %
	(64) Exbio Olomouc	>>> 2	Negative	1,5 %
	(80) DiaMed	>>> 25	Negative	19 %
	(159) Grifols	>>> 42	Negative	31 %
	(174) IVT Imuno	>>> 1	Negative	0,74 %
	(203) ANTITOXIN	>>> 1	Negative	0,74 %
Total per sample: n = 135		Success: 100 %		
E2 and S2	(6) APR	>>> 1	Negative	0,74 %
	(14) Bio-Rad	>>> 61	Negative	45 %
	(40) Ortho Clinical Diagnostics	>>> 2	Negative	1,5 %
	(64) Exbio Olomouc	>>> 2	Negative	1,5 %
	(80) DiaMed	>>> 25	Negative	19 %
	(159) Grifols	>>> 42	Negative	31 %
	(174) IVT Imuno	>>> 1	Negative	0,74 %
	(203) ANTITOXIN	>>> 1	Negative	0,74 %
Total per sample: n = 135		Success: 100 %		
Total success: 100 %				

(741) Antibody screening (IAT, blood donor)

E1 and S1	(0) not specified	>>> 1	Positive	1,1 %
	(6) APR	>>> 4	Positive	4,6 %
	(14) Bio-Rad	>>> 33	Positive	38 %
	(40) Ortho Clinical Diagnostics	>>> 1	Positive	1,1 %
	(64) Exbio Olomouc	>>> 1	Positive	1,1 %
	(80) DiaMed	>>> 12	Positive	14 %
	(159) Grifols	>>> 21	Positive	24 %
	(172) Immucor	>>> 14	Positive	16 %

EQA round: IH4/22 - Blood Group Serology

Deadline: 18.11.2022

Test	Sample	Group	N	Result	N _{rel}
Total per sample: n = 87 Success: 100 %					
E2 and S2	(0)	not specified	>>>	1 Positive	1,1 %
	(6)	APR	>>>	4 Positive	4,6 %
	(14)	Bio-Rad		1 Not specified	1,1 %
			>>>	32 Positive	37 %
	(40)	Ortho Clinical Diagnostics	>>>	1 Positive	1,1 %
	(64)	Exbio Olomouc	>>>	1 Positive	1,1 %
	(80)	DiaMed	>>>	12 Positive	14 %
	(159)	Grifols	>>>	21 Positive	24 %
	(172)	Immucor	>>>	14 Positive	16 %
Total per sample: n = 87 Success: 99 %					
Total success: 99 %					

(743) Antibody screening (IAT, recipient)

E1 and S1	(0)	not specified	>>>	1 Positive	0,69 %
	(6)	APR	>>>	2 Positive	1,4 %
	(14)	Bio-Rad	>>>	64 Positive	44 %
	(40)	Ortho Clinical Diagnostics	>>>	2 Positive	1,4 %
	(80)	DiaMed	>>>	25 Positive	17 %
	(159)	Grifols	>>>	44 Positive	31 %
	(172)	Immucor	>>>	6 Positive	4,2 %
Total per sample: n = 144 Success: 100 %					
E2 and S2	(0)	not specified	>>>	1 Positive	0,69 %
	(6)	APR	>>>	2 Positive	1,4 %
	(14)	Bio-Rad	>>>	64 Positive	44 %
	(40)	Ortho Clinical Diagnostics	>>>	2 Positive	1,4 %
	(80)	DiaMed	>>>	25 Positive	17 %
	(159)	Grifols	>>>	44 Positive	31 %
	(172)	Immucor	>>>	6 Positive	4,2 %
Total per sample: n = 144 Success: 100 %					
Total success: 100 %					

(745) Antibody screening (IAT, pregnant)

E1 and S1	(6)	APR	>>>	2 Positive	1,7 %
	(14)	Bio-Rad	>>>	50 Positive	43 %
	(40)	Ortho Clinical Diagnostics	>>>	2 Positive	1,7 %
	(64)	Exbio Olomouc	>>>	1 Positive	0,87 %
	(80)	DiaMed	>>>	18 Positive	16 %
	(159)	Grifols	>>>	36 Positive	31 %
	(172)	Immucor	>>>	6 Positive	5,2 %
Total per sample: n = 115 Success: 100 %					
E2 and S2	(6)	APR	>>>	2 Positive	1,7 %
	(14)	Bio-Rad	>>>	50 Positive	43 %
	(40)	Ortho Clinical Diagnostics	>>>	2 Positive	1,7 %
	(64)	Exbio Olomouc	>>>	1 Positive	0,87 %
	(80)	DiaMed	>>>	18 Positive	16 %
	(159)	Grifols	>>>	36 Positive	31 %
	(172)	Immucor	>>>	6 Positive	5,2 %
Total per sample: n = 115 Success: 100 %					
Total success: 100 %					

(747) Antibody screening (enzyme test)

E1 and S1	(0)	not specified	>>>	1 Positive	0,92 %
	(14)	Bio-Rad	>>>	50 Positive	46 %
	(40)	Ortho Clinical Diagnostics	>>>	2 Positive	1,8 %
	(80)	DiaMed		1 Negative	0,92 %
			>>>	18 Positive	17 %
	(159)	Grifols		1 Not specified	0,92 %
			>>>	35 Positive	32 %
	(172)	Immucor	>>>	1 Positive	0,92 %
Total per sample: n = 109 Success: 98 %					
E2 and S2	(0)	not specified	>>>	1 Positive	0,92 %
	(14)	Bio-Rad	>>>	50 Positive	46 %
	(40)	Ortho Clinical Diagnostics	>>>	2 Positive	1,8 %
	(80)	DiaMed	>>>	19 Positive	17 %
	(159)	Grifols	>>>	36 Positive	33 %
	(172)	Immucor	>>>	1 Positive	0,92 %
Total per sample: n = 109 Success: 100 %					
Total success: 98 %					

(750) Antibody identification

E1 and S1	(0)	not specified	>	44 anti-E; anti-Fya	88 %
-----------	-----	---------------	---	---------------------	------

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH4/22 - Blood Group Serology

Deadline: 18.11.2022

Test		N	Result	N _{rel}
Sample	Group			
E1 and S1 (0) not specified		1	anti-E; anti-Fya; anti-Cw	2,0 %
		>>> 5	anti-E; anti-Fya; anti-Wra	10 %
-----	Total per sample: n = 50	-----	Success: 98 %	-----
E2 and S2 (0) not specified		>>> 49	anti-D	98 %
		1	anti-D; anti-Cw	2,0 %
-----	Total per sample: n = 50	-----	Success: 98 %	-----
Total success: 98 %				
(752) Antibody titre, Sample 1: 1st antibody				
E1 and S1 (0) not specified		± 3	titre 4	9,7 %
		± 8	titre 8	26 %
		± 4	titre 16	13 %
		± 12	titre 32	39 %
		± 3	titre 64	9,7 %
		± 1	titre 128	3,2 %
-----	Total per sample: n = 31	-----	Success (only evaluated results): not assessed	-----
(753) Antibody titre, Sample 1: 2nd antibody				
E1 and S1 (0) not specified		± 10	titre 8	29 %
		± 16	titre 16	47 %
		± 6	titre 32	18 %
		± 2	titre 64	5,9 %
-----	Total per sample: n = 34	-----	Success (only evaluated results): not assessed	-----
(754) Antibody titre, Sample 1: 3rd antibody				
E1 and S1 (0) not specified		± 3	titre 16	75 %
		± 1	titre 32	25 %
-----	Total per sample: n = 4	-----	Success (only evaluated results): not assessed	-----
(756) Antibody titre, Sample 2: 1st antibody				
E2 and S2 (0) not specified		± 2	titre 256	5,9 %
		± 3	titre 32	8,8 %
		± 16	titre 64	47 %
		± 13	titre 128	38 %
-----	Total per sample: n = 34	-----	Success (only evaluated results): not assessed	-----
Set 3				
(760) Crossmatch				
S1	All results	>>> 130	Crossmatch successful	100 %
-----	Total per sample: n = 130	-----	Success: 100 %	-----
S2	All results	>>> 130	Crossmatch successful	100 %
-----	Total per sample: n = 130	-----	Success: 100 %	-----
Total success: 100 %				
(761) Crossmatch (segment K1)				
S1	(0) not specified	>>> 130	Positive test	100 %
-----	Total per sample: n = 130	-----	Success: 100 %	-----
S2	(0) not specified	>>> 130	Negative test	100 %
-----	Total per sample: n = 130	-----	Success: 100 %	-----
Total success: 100 %				
(762) Serve transfusion product (segment K1)				
S1	(0) not specified	± 129	Impossible, risk of haemolysis	99 %
		± 1	Decision depends on results of other tests not performed in our laboratory	0,77 %
-----	Total per sample: n = 130	-----	Success (only evaluated results): not assessed	-----
S2	(0) not specified	± 4	Impossible, risk of haemolysis	3,1 %
		± 73	Decision depends on results of other tests not performed in our laboratory	56 %
		± 32	Only if more suitable products are not available	25 %
		± 21	Possible	16 %
-----	Total per sample: n = 130	-----	Success (only evaluated results): not assessed	-----
(764) Crossmatch (segment K2)				
S1	(0) not specified	>>> 130	Negative test	100 %
-----	Total per sample: n = 130	-----	Success: 100 %	-----
S2	(0) not specified	>>> 130	Positive test	100 %
-----	Total per sample: n = 130	-----	Success: 100 %	-----
Total success: 100 %				
(765) Serve transfusion product (segment K2)				
S1	(0) not specified	± 2	Impossible, risk of haemolysis	1,5 %
		± 75	Decision depends on results of other tests not performed in our laboratory	58 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH4/22 - Blood Group Serology

Deadline: 18.11.2022

Test		N	Result	N _{rel}
Sample	Group			
S1	(0) not specified	± 33	Only if more suitable products are not available	25 %
		± 20	Possible	15 %
----- Total per sample: n = 130 -----		Success (only evaluated results): not assessed		-----
S2	(0) not specified	± 128	Impossible, risk of haemolysis	98 %
		± 2	Decision depends on results of other tests not performed in our laboratory	1,5 %
----- Total per sample: n = 130 -----		Success (only evaluated results): not assessed		-----

st_kl End of report

Printed: 26.11.2022